CRISPR Therapeutics AG — Director's Dealing 2018

Jun 8, 2018

SEC Form 4/A — Form 4/A

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-06-05

Reporting Person: EMSTER KURT VON (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Shares	1237202	Indirect

Footnotes

F1: On June 7, 2018, Kurt von Emster ("Reporting Person") mistakenly filed a Form 4 reporting an option exercise for CRISPR Therapeutics AG ("CRISPR"). Reporting Person did not exercise CRISPR options.

F2: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F3: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.